Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024
August 01, 2023 at 11:00 pm EDT
Share
Shin Nippon Biomedical Laboratories, Ltd. provided consolidated earnings guidance for the six months ending September 30, 2023 and full year ending March 31, 2024. For the six months, the company expects revenue of JPY 11,668 million, operating profit of JPY 2,260 million, profit attributable to owners of parent of JPY 2,280 million and earnings per share of JPY 54.77.
For the full year, the company expects revenue of JPY 30,368 million, operating profit of JPY 5,020 million, profit attributable to owners of parent of JPY 4,780 million and earnings per share of JPY 114.81.
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. is a Japan-based company mainly engaged in the provision of clinical trials and drug development services for pharmaceutical companies. The Company has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. 
